Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 1;44(5):405-410.
doi: 10.1097/INF.0000000000004675. Epub 2024 Dec 20.

Health-related Quality of Life in Children and Adolescents After Successful Treatment of Chronic Hepatitis C With Sofosbuvir/Velpatasvir: One-year Outcomes

Affiliations

Health-related Quality of Life in Children and Adolescents After Successful Treatment of Chronic Hepatitis C With Sofosbuvir/Velpatasvir: One-year Outcomes

Maria Pokorska-Śpiewak et al. Pediatr Infect Dis J. .

Abstract

Background and aims: The aim of this study was to assess the health-related quality of life (HRQL) of children with chronic hepatitis C (CHC) at 1 year after the effective treatment with sofosbuvir/velpatasvir (SOF/VEL).

Methods: All 50 patients treated for CHC with a fixed dose SOF/VEL in the noncommercial, nonrandomized, open-label PANDAA-PED study achieved sustained virologic response at 12 weeks after the end of treatment. Evaluation of HRQL at 1-year posttreatment was compared with the baseline (before the treatment) assessment. KIDSCREEN-27 questionnaires, which included 5 dimensions of HRQL, for child self-reporting and parent proxy reporting were used. The normal range for the population was set to T values of 40-60 points. Child-parent agreement was analyzed using the intraclass correlation coefficient (ICC).

Results: Mean T values were within the normal range for all HRQL dimensions. A significant improvement in "autonomy & parent relation" in children's self-assessment (from 48.3 to 51.5, P = 0.03) was observed. In parent proxy assessment, a significant decrease occurred in "school" dimension (from 49.5 to 45.8, P = 0.03), which was not revealed at 3-month posttreatment. Older age was associated with worse HRQL scores in all dimensions. Evaluation of the ICC for child self-reports versus parent proxy reports revealed poor-to-moderate agreement for most single measures, lower than at 3-month posttreatment analysis.

Conclusions: This is the first study to present the long-term influence of treatment with direct-acting antivirals on patient-reported outcomes in children. At 1 year after effective treatment with SOF/VEL, an improvement in some areas of children's well-being was revealed, which may indicate also some patient-reported outcomes benefits of direct-acting antiviral therapy. Despite the improvement in the child self-report of "autonomy & parent relation," there was a more pronounced discrepancy between children self-reports and parents proxy reports in all dimensions of HRQL. Older patients' age correlated with worse HRQL assessment. If this finding is mediated by the duration of hepatitis C virus infection, it would support recommendation for the treatment of younger children.

Keywords: children; health-related quality of life; hepatitis C virus; sofosbuvir/velpatasvir.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

FIGURE 1.
FIGURE 1.
Flowchart of participants and their parents who made HRQL assessments at baseline and 12-month posttreatment.
FIGURE 2.
FIGURE 2.
Changes in the assessment of 5 dimensions of HRQL by children and their parents at 3-month and 12-month posttreatment compared to baseline (before the treatment). Bars represent mean T values and horizontal lines indicate 95% confidence intervals. Data were compared using ANOVA (repeated measures analysis of variance). P-values were indicated only if they were <0.05.

Similar articles

References

    1. Younossi Z, Papatheodoridis G, Cacoub P, et al. . The comprehensive outcomes of hepatitis C virus infection: a multi-faceted chronic disease. J Viral Hepat. 2018;25:6–14. - PubMed
    1. Younossi ZM, Stepanova M, Racila A, et al. . Long-term benefits of sustained virologic response for patient-reported outcomes in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2020;18:468–476.e11. - PubMed
    1. Indolfi G, Gonzalez-Peralta RP, Jonas MM, et al. ; Hepatology Committee of the ESPGHAN. ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource-limited settings. J Pediatr Gastroenterol Nutr. 2024;78:957–972. - PubMed
    1. Indolfi G, Easterbrook P, Giometto S, et al. . Efficacy and safety of DAA in children and adolescents with chronic HCV infection: a systematic review and meta-analysis. Liver Int. 2024;44:663–681. - PubMed
    1. Younossi ZM, Stepanova M, Schwarz KB, et al. . Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin. J Viral Hepat. 2018;25:354–362. - PubMed